C. Weyer
About
C. Weyer is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Physiology.
According to data from OpenAlex, C. Weyer has authored 40 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Endocrinology, Diabetes and Metabolism, 12 papers in Surgery and 10 papers in Physiology. Recurrent topics in C. Weyer's work include Diabetes Treatment and Management (13 papers), Diabetes Management and Research (12 papers) and Pancreatic function and diabetes (12 papers). C. Weyer is often cited by papers focused on Diabetes Treatment and Management (13 papers), Diabetes Management and Research (12 papers) and Pancreatic function and diabetes (12 papers). C. Weyer collaborates with scholars based in United States, Germany and Switzerland. C. Weyer's co-authors include Richard E. Pratley, Clifton Bogardus, P. Antonio Tataranni, James E. Foley, Orville Kolterman, S. Strobel, David Maggs, Éric Ravussin, Mark Fineman and Søren Snitker and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Diabetes Care and Diabetes.
In The Last Decade
C. Weyer
40 papers receiving 4.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| C. Weyer United States | 28 | 1.9k | 1.7k | 1.2k | 1.2k | 943 | 40 | 4.4k | ||
| Marilyn Ader United States | 33 | 2.2k 1.2× | 1.8k 1.1× | 880 0.7× | 1.1k 1.0× | 1.4k 1.5× | 50 | 4.8k | ||
| Penny Wallace United States | 32 | 1.9k 1.0× | 2.1k 1.2× | 1.1k 0.9× | 1.0k 0.9× | 1.6k 1.7× | 44 | 4.9k | ||
| B. L. Grégoire Nyomba Canada | 36 | 1.3k 0.7× | 1.8k 1.1× | 971 0.8× | 590 0.5× | 1.4k 1.5× | 79 | 4.9k | ||
| Stefania Camastra Italy | 38 | 1.9k 1.0× | 2.1k 1.2× | 968 0.8× | 1.9k 1.6× | 1.7k 1.8× | 66 | 5.2k | ||
| Ronald L. Prigeon United States | 32 | 2.8k 1.5× | 1.4k 0.8× | 623 0.5× | 2.3k 2.0× | 1.3k 1.4× | 43 | 5.0k | ||
| M. Diamant Netherlands | 36 | 2.5k 1.3× | 1.1k 0.6× | 691 0.6× | 1.0k 0.9× | 1.5k 1.6× | 82 | 5.0k | ||
| S. Matthäei Germany | 29 | 1.5k 0.8× | 1.2k 0.7× | 578 0.5× | 835 0.7× | 1.4k 1.5× | 84 | 3.7k | ||
| Richard M. Watanabe United States | 30 | 1.4k 0.7× | 1.4k 0.8× | 639 0.5× | 656 0.6× | 964 1.0× | 61 | 3.8k | ||
| L. Groop Sweden | 30 | 1.3k 0.7× | 1.1k 0.7× | 499 0.4× | 873 0.8× | 1.1k 1.2× | 57 | 3.5k | ||
| James C Beard United States | 26 | 2.0k 1.1× | 1.2k 0.7× | 515 0.4× | 1.4k 1.2× | 936 1.0× | 39 | 4.0k |
Countries citing papers authored by C. Weyer
Since
Specialization
Citations
This map shows the geographic impact of C. Weyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Weyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Weyer more than expected).
Fields of papers citing papers by C. Weyer
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by C. Weyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Weyer. The network helps show where C. Weyer may publish in the future.
Co-authorship network of co-authors of C. Weyer
This figure shows the co-authorship network connecting the top 25 collaborators of C. Weyer. A scholar is included among the top collaborators of C. Weyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Weyer. C. Weyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Heinemann, Lutz, et al.. (2009). Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp. Experimental and Clinical Endocrinology & Diabetes. 105(3). 140–144.
2.
Roth, Jonathan D., James L. Trevaskis, Julie Wilson, et al.. (2008). Antiobesity effects of the β-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. International Journal of Obesity. 32(8). 1201–1210.
3.
Stefan, Norbert, Michael Stümvoll, C. Weyer, et al.. (2004). Exaggerated insulin secretion in Pima Indians and African‐Americans but higher insulin resistance in Pima Indians compared to African‐Americans and Caucasians. Diabetic Medicine. 21(10). 1090–1095.
4.
Ratner, Robert E., Richard A. Dickey, Mark Fineman, et al.. (2004). Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial. Diabetic Medicine. 21(11). 1204–1212.
5.
Hollander, Priscilla, Robert E. Ratner, Mark Fineman, et al.. (2003). Addition of pramlintide to insulin therapy lowers HbA 1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obesity and Metabolism. 5(6). 408–414.
6.
Maggs, David, Larry Z. Shen, S. Strobel, et al.. (2003). Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metabolism. 52(12). 1638–1642.
7.
Heise, Tim, et al.. (2002). Wege zur Verbesserung der Qualität der antihypertensiven Therapie bei Diabetes mellitus - Ergebnisse des strukturierten Hypertonie Behandlungs- und Schulungsprogrammes -. Zeitschrift für Gastroenterologie. 40(Suppl. 1). 27–32.
8.
Fineman, Mark, C. Weyer, David Maggs, S. Strobel, & Orville Kolterman. (2002). The Human Amylin Analog, Pramlintide, Reduces Postprandial Hyperglucagonemia in Patients with Type 2 Diabetes Mellitus. Hormone and Metabolic Research. 34(9). 504–508.
9.
Weyer, C., Barbora Vozarova, Éric Ravussin, & PA Tataranni. (2001). Changes in energy metabolism in response to 48 h of overfeeding and fasting in Caucasians and Pima Indians. International Journal of Obesity. 25(5). 593–600.
10.
Pratley, Richard E. & C. Weyer. (2001). The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia. 44(8). 929–945.
11.
Weyer, C.. (2001). Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and Hyperinsulinemia. The Journal of Clinical Endocrinology & Metabolism. 86(5). 1930–1935.
12.
Weyer, C., David J. Maggs, Andrew Young, & Orville Kolterman. (2001). Amylin Replacement With Pramlintide as an Adjunct to Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: A Physiological Approach Toward Improved Metabolic Control. Current Pharmaceutical Design. 7(14). 1353–1373.
13.
Weyer, C., James E. Foley, Clifton Bogardus, P. Antonio Tataranni, & Richard E. Pratley. (2000). Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance. Diabetologia. 43(12). 1498–1506.
14.
Weyer, C., Kristin A. Hanson, Clifton Bogardus, & Richard E. Pratley. (2000). Long-term changes in insulin action and insulin secretion associated with gain, loss, regain and maintenance of body weight. Diabetologia. 43(1). 36–46.
15.
Weyer, C., Clifton Bogardus, & Richard E. Pratley. (1999). Metabolic factors contributing to increased resting metabolic rate and decreased insulin-induced thermogenesis during the development of type 2 diabetes.. Diabetes. 48(8). 1607–1614.
16.
Heinemann, Lutz, et al.. (1999). Time‐action profile of the soluble, fatty acid acylated, long‐acting insulin analogue NN304. Diabetic Medicine. 16(4). 332–338.
17.
Rave, Klaus, Tim Heise, C. Weyer, et al.. (1998). Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects. Diabetic Medicine. 15(9). 747–751.
18.
Weyer, C., et al.. (1998). Implications of the traditional and the new ACSM Physical Activity Recommendations on weight reduction in dietary treated obese subjects. International Journal of Obesity. 22(11). 1071–1078.
19.
Schierl, Rudolf, et al.. (1998). Urinary excretion of platinum from platinum industry workers.. Occupational and Environmental Medicine. 55(2). 138–140.
20.
Redecker, P., C. Weyer, & D. Grube. (1996). Rat and gerbil pinealocytes contain the synaptosomal‐associated protein 25 (SNAP‐25). Journal of Pineal Research. 21(1). 29–34.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Marilyn Ader Breakdown of academic impact, for papers by Penny Wallace Breakdown of academic impact, for papers by B. L. Grégoire Nyomba Breakdown of academic impact, for papers by Stefania Camastra Breakdown of academic impact, for papers by Ronald L. Prigeon Breakdown of academic impact, for papers by M. Diamant Breakdown of academic impact, for papers by S. Matthäei Breakdown of academic impact, for papers by Richard M. Watanabe Breakdown of academic impact, for papers by L. Groop Breakdown of academic impact, for papers by James C Beard